Drugs with potential to lower the seizure threshold are numerous and diverse. Whether they contribute to clinically overt seizures depends on the dosage in which they are taken, the time-course of their effects and the susceptibility of the patient. Crucially, however, their contribution to seizure risk is potentially modifiable.
Departments of Clinical Pharmacology and Neuro-Intensive Care, St George's, University of London and St George's University Hospitals NHS Foundation Trust, Cranmer Terrace, London, SW17 0RE, UK
Correspondence to Andrew W. Hitchings, Senior Lecturer in Clinical Pharmacology and Honorary Consultant in Neuro-Intensive Care, St George's, University of London and St George's University Hospitals NHS Foundation Trust Cranmer Terrace, London SW17 0RE, UK. E-mail: firstname.lastname@example.org
Editor: R E Ferner, MSc, MD, FRCP, Director of the West Midlands Centre for Adverse Drug Reaction Reporting and Consultant Physician at City Hospital, Birmingham, UK. Assistant Editor: Mr C Anton, MA, MEng. Editorial Board: Australia: Dr M Kennedy, Professor G M Shenfield, Denmark: Professor J S Schou; England: Dr J K Aronson; India: Professor N Gogtay; Netherlands: Professor C J van Boxtel, Dr B H Ch Stricker; New Zealand: Dr T Maling; Scotland: Dr D N Bateman; Wales: Professor P A Routledge.